Research programme: DYRK inhibitors - Diaxonhit
Latest Information Update: 05 Jul 2013
At a glance
- Originator Diaxonhit
- Class Small molecules
- Mechanism of Action DYRK kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Down syndrome
Most Recent Events
- 04 Jul 2013 Preclinical trials in Down syndrome in USA (unspecified route)
- 04 Jul 2013 Preclinical trials in Alzheimer's disease in USA (unspecified route)